KORU Medical Systems, Inc. reported second quarter fiscal 2026 financial results and updated full-year guidance for the year ending December 31, 2025. Net revenues grew 18% to $12.0 million, driven by a 12.4% increase in domestic core sales and a 59.1% surge in international core revenue. Gross profit rose 20% to $7.8 million with a gross margin of 65.1%, while net income improved 222% to $0.25 million, or $0.01 per diluted share. The company adjusted its full-year 2026 revenue guidance to $47.5–$48.5 million and raised gross margin expectations to 62–64%. Strategic updates include withdrawing the U.S. 510(k) application for FreedomEDGE with Phesgo, shifting oncology strategy to higher-volume molecules, acquiring a connected monitoring technology asset, and entering a multi-year supply agreement. KORU Medical Systems operates in the medical device industry, developing and commercializing subcutaneous infusion solutions.

KORU Medical Systems, Inc. entered into an amendment to its manufacturing and supply agreement with Command Medical Products, LLC on June 24, 2026, which extends the initial term of the agreement to December 31, 2031, and establishes Command as the exclusive manufacturer for a limited set of products. The amendment also modifies pricing and payment terms, clarifies intellectual property ownership, and requires Command to qualify a second manufacturing site by December 31, 2027. KORU Medical Systems, Inc. operates in the medical device industry and manufactures subassemblies, needle sets, and tubing products.